Journal article 1134 views 1319 downloads
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok,
Vanna Chiarion-Sileni,
Rene Gonzalez,
Piotr Rutkowski,
Jean-Jacques Grob,
C. Lance Cowey,
Christopher D. Lao,
John Wagstaff,
Dirk Schadendorf,
Pier F. Ferrucci,
Michael Smylie,
Reinhard Dummer,
Andrew Hill,
David Hogg,
John Haanen,
Matteo S. Carlino,
Oliver Bechter,
Michele Maio,
Ivan Marquez-Rodas,
Massimo Guidoboni,
Grant McArthur,
Celeste Lebbé,
Paolo A. Ascierto,
Georgina V. Long,
Jonathan Cebon,
Jeffrey Sosman,
Michael A. Postow,
Margaret K. Callahan,
Dana Walker,
Linda Rollin,
Rafia Bhore,
F. Stephen Hodi,
James Larkin
New England Journal of Medicine, Volume: 377, Issue: 14, Pages: 1345 - 1356
Swansea University Author: John Wagstaff
-
PDF | Version of Record
Download (320.53KB)
DOI (Published version): 10.1056/nejmoa1709684
Abstract
This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19%...
| Published in: | New England Journal of Medicine |
|---|---|
| ISSN: | 0028-4793 1533-4406 |
| Published: |
Massachusetts Medical Society
2017
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa37736 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
This is the three year update of a randomised phase III trial in patients with locally advanced inoperable stage III or stage IV melanoma. 1296 patients were radomised to receive either ipilimumab (Ipi), nivolumab (Nivo) or both antibodies (Ipi+Nivo). Complete responses were seen in 5, 16 & 19% of patients in the Ipi, Nivo and Ipi+Nivo groups respectively. Partial responses were seen in 14, 28 & 29% of patients respectively. With a minimum follow up of 28 months 3 year overall survivals were 32, 52 & 58% in the Ipi, Nivo & Ipi+Nivo respectively. In patients with braf mutations the three year survivals were 37, 56 & 68% in the three groups. This compares with a three year survival of 44% in the dabrafenib plus trametinib arm of the COMBI-D trial (J. Clin. Oncol. 2017 Dob: 10.1200/JCO.2017.74.1025). These data represent practice changing data for oncologist who treat melanoma and life changing treatment for patients with metastatic melanoma. |
|---|---|
| Keywords: |
Melanoma, Ipilimumab, Nivolumab, Survival |
| College: |
Faculty of Medicine, Health and Life Sciences |
| Issue: |
14 |
| Start Page: |
1345 |
| End Page: |
1356 |